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In a previous issue of Critical Care, Prowle and colleagues 
describe the results of a cohort study in which incidence 
and attributable mortality of bloodstream infection (BSI) 
were investigated in university-aﬃ  liated hospitals [1]. 
Th e cohort included 6,339 patients with an ICU stay >72 
hours, of which 330 developed an ICU-acquired BSI. 
Mortality associated with BSI was 41.2% and thereby 
sub stantially higher compared to patients without BSI 
(22.5%). After adjustment for confounding covariates, 
BSI remained an independent risk factor for death 
(hazard ratio 2.9, 95% conﬁ dence interval 2.4 to 3.5). Th e 
study by Prowle and colleagues, however, goes beyond 
impact estimates for patients who are aﬀ ected by this 
infectious complication. Th e investigators linked the 
attributable risk of death to the incidence of BSI, which 
was approximately 5% in this cohort. Th e authors state 
that, taking into account the low incidence, the overall 
impact of nosocomial BSI on the total study population 
was small as it only caused a decrease in overall survival 
of approximately 1%. As such, the study by Prowle and 
colleagues is remarkable as it evaluates the deleterious 
impact of BSI in bacteremic patients and in the overall 
ICU cohort.
For what concerns the impact for patients with BSI, the 
study results concur with those of other investigators 
who found dramatic excess mortality rates, albeit that 
some researchers reported attributable mortality rates of 
non-signiﬁ cant proportions [2-4]. Within certain conﬁ -
dence limits, all of these estimates might match reality as 
clinical outcomes are multifactorial and variable depend-
ing on the speciﬁ c characteristics of the study cohort [5].
More unusual and controversial is to express the excess 
mortality of BSI for the overall population. Even in a 
situation where substantial excess mortality was noted in 
the bacteremic cohort, the deleterious impact appears to 
be of minor importance when using the overall cohort as 
denominator. Th is ﬁ nding has several consequences that 
must be addressed. As the authors themselves point out, 
survival beneﬁ t of untargeted interventions to prevent 
BSI is hardly feasible, and any claims of improved survival 
from interventions to reduce BSI must therefore be 
interpreted cautiously. We fully concur with these 
statements. As BSIs hardly aﬀ ect overall mortality, huge 
trials in prevention are necessary to demonstrate beneﬁ ts 
in mortality. One might question whether mortality is, 
per se, the best outcome variable. As already mentioned, 
mortality always is a product of many components. Also, 
plenty of studies, including the present one by Prowle 
and colleagues, show that BSIs do result in a signiﬁ cant 
excess risk of death. It seems appropriate, therefore, that 
infection rate in itself, and not mortality, is the best suited 
outcome variable. Th e data provided by Prowle and 
colleagues show that, for interventional studies in 
infection prevention, study power should be calculated as 
a function of a predeﬁ ned reduction in infection rate, 
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Mortality associated with nosocomial bloodstream 
infection is multifactorial. Source of infection, 
etiology, age, underlying disease, acute illness, and 
appropriateness of antimicrobial therapy all contribute 
to the fi nal outcome. As such, estimates of mortality 
attributable to bloodstream infection may diff er largely 
according to the presence or absence of risk factors 
in distinct patient populations. The adverse eff ect of 
nosocomial bloodstream infection for the individual 
patient is substantial, with about a doubling of the 
risk of death. Yet, in settings with a high standard of 
care in terms of infection prevention and control, 
the occurrence rate of bloodstream infection is 
relatively low and therefore its impact on overall ICU 
mortality rather limited. As a consequence, untargeted 
interventional studies focused on infection prevention 
should use occurrence rate of infection rather than 
mortality as outcome variable.
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rather than decreased mortality. Vice versa, study results 
of such trials indicating a reduced infection risk but 
without diﬀ erence in mortality should not be taken as a 
justi ﬁ  cation of non-adherence, on the condition that 
associated costs are not excessive.
Although mathematically correct, the approach of 
considering the impact of BSI on population level calls 
for some vigilance. By diluting the eﬀ ect of infection 
there exists a risk of downplaying the importance of a 
severe complication. Even though Prowle and colleagues 
clearly do not enlighten their study results with this 
purpose, the present data could be used as an argument 
to minimize the problem and a reason not to invest in 
infection prevention. In this way, the consequences of 
many other severe complications can be downgraded to 
apparently negligible proportions. For example, acute 
kidney injury with need for renal replacement therapy is 
well-known to be one of the strongest risk factors for 
death in patients with severe burn injury. Acute kidney 
injury occurs in approximately 3% of severely burned 
patients and is associated with a mortality rate of about 
30% [6]. Th e average baseline mortality in burn patients 
has been estimated to be 5% [7]. Based on these ﬁ gures, it 
can be calculated that acute kidney injury increases 
mortality by only 0.9% (from 4.85% to 5.75%). Th is 
example illustrates how the impact of complications can 
be diminished by alterations in denominator.
Th e study by Prowle and colleagues demonstrates that 
assessing the impact of BSI should preferably be 
performed on the patient group aﬀ ected as many other 
ICU patients have only a very low risk proﬁ le for the 
acquisition of nosocomial BSI. Diluting the impact of 
infection to the overall population, however, illustrates 
that infection prevention studies should use infection 
rates as endpoints, as proving substantial beneﬁ ts in 
survival does not seem to be achievable.
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